Background: Amplification of HER2 is seen in 20-30% of breast cancer cases. Measurement of HER2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. The aim of our study was to evaluate HER2 amplification status in malignant and benign breast tumors by differential PCR (dPCR). Materials and Methods: The genomic DNA was ex...

background: one million people are diagnosed with gastric cancer (gc) annually and the prognosis for patients with advanced gc or gastroesophageal junction (gej) cancer is usually poor with a median survival time of 8 to 10 months. recent reports have identified that anti her2 target therapy improved the median survival rate in patients with her2 positive gc; but a wide range of her2 overexpres...

Single chain Fragment variable (scFv) is an antibody fragment consisting variable regions of heavy and light chains. scFvs enhance their penetrability into tissues while maintaining specific affinity and having low immunogenicity. Insoluble inclusion bodies are formed when scFvs are expressed in reducing bacterial cytoplasm. One strategy for obtaining functionally active scFv is to translocate ...

background: amplification of her2 is seen in 20-30% of breast cancer cases. measurement of her2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. the aim of our study was to evaluate her2 amplification status in malignant and benign breast tumors by differential pcr (dpcr). materials and methods: the genomic dna was extra...

introduction: her2/neu, a member of the epidermal growth factor receptor family, has been shown to be over-expressed in some tumors. the purpose of this study was to determine the salivary levels and tissue expression of her2/neu in patients with head and neck squamous cell carcinoma (hnscc) and their correlation with clinicopathologic parameters.   materials and methods: enzyme-linked immunoso...

Objetivo. Analizar las diferencias en la presentación de variables clínico-patológicas, acuerdo con expresión proteica GRB7, tumores HER2 positivos mujeres colombianas cáncer mama invasivo, diagnosticado entre los años 2013 y 2015 el Instituto Nacional Cancerología E.S.E (INC). Métodos. Se incluyeron 158 pacientes diagnóstico confirmado ductal invasivo. evaluó receptores hormonales (receptor es...